The data presented here highlight the rapid advancements that have been made in the understanding of gut microbiome–bile-metabolism–FXR interactions, their relevance to the pathogenesis of CDI and their implications for therapeutic intervention in rCDI. The gene discussed is NR1H4; the disease is clostridium difficile infection.